Pegadricase is a Recombinant Enzyme owned by Polaris Pharmaceuticals, and is involved in 9 clinical trials, of which 6 were completed, and 3 are ongoing.

SEL-212 acts by stimulating the body's immune system for the production of antibodies which helps in neutralizing the foreign substances. They induce antigen-specific immune tolerance and help in the treatment of the disease.

The revenue for Pegadricase is expected to reach a total of $1.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Pegadricase NPV Report.

Pegadricase was originated by Phoenix Pharmacologics and is currently owned by Polaris Pharmaceuticals. Swedish Orphan Biovitrum is the other company associated in development or marketing of Pegadricase.

Pegadricase Overview

SEL-212 is under development for the treatment of chronic refractory and tophaceous gout, and hyperuricemia. It is administered through intravenous and intramuscular route. It is a combination of pegsiticase (SEL-037) and SVP-rapamycin (SEL-110). It is based on tolerogenic synthetic vaccine particle (SVP) platform. It was also under development for Lesch-Nyhan syndrome, hyperuricemia and tumor lysis syndrome.

Swedish Orphan Biovitrum Overview

Swedish Orphan Biovitrum (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of a few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation and genetic and metabolic diseases. The company also provides innovative treatment for conditions such as amyotrophic lateral sclerosis (ALS) and Hemophilia A. Sobi also manufactures and markets specialty products for rare diseases for partner companies. The company has operational presence in Europe, the Middle East, North America, Russia, and Asia. Sobi is headquartered in Stockholm, Sweden.

The company reported revenues of (Swedish Krona) SEK15,529 million for the fiscal year ended December 2021 (FY2021), an increase of 1.8% over FY2020. In FY2021, the company’s operating margin was 24%, compared to an operating margin of 31.6% in FY2020. In FY2021, the company recorded a net margin of 17.3%, compared to a net margin of 21.3% in FY2020. The company reported revenues of SEK3,999 million for the third quarter ended September 2022, an increase of 3.2% over the previous quarter.

Quick View – Pegadricase

Report Segments
  • Innovator
Drug Name
  • Pegadricase
Administration Pathway
  • Intramuscular
  • Intravenous
Therapeutic Areas
  • Metabolic Disorders
  • Musculoskeletal Disorders
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.